Bee Venom Peptide Melittin Dramatically Reduces Colitis Symptoms and Colon Damage in Mice | Research

The takeaway

Melittin from bee venom nearly eliminated colon tissue damage in a mouse model of ulcerative colitis and enhanced the effectiveness of standard treatment.

Near-complete elimination of colon tissue damage
Melittin almost fully reversed histological damage from DSS-induced colitis, with additional antioxidant effects

What the researchers found

Melittin — a peptide from bee venom — dramatically improved clinical symptoms of ulcerative colitis in a DSS-induced mouse model, both as a standalone treatment and in combination with sulfasalazine (a standard UC drug). The peptide nearly eliminated histological damage in colon tissue and significantly reduced inflammation. Melittin also showed antioxidant effects by restoring the oxidant/antioxidant balance in damaged tissue. When used alongside sulfasalazine, melittin enhanced the conventional drug's therapeutic effect while attenuating its adverse effects.

Why it matters

Ulcerative colitis affects millions of people, and current treatments often have inadequate efficacy or significant side effects. This study suggests melittin could serve dual roles: as a standalone anti-inflammatory agent and as a combination partner that boosts the effectiveness of existing drugs while reducing their toxicity. The antioxidant mechanism adds another dimension beyond simple inflammation suppression.

How the study worked

C57BL/6 male mice were given dextran sulfate sodium (DSS) in drinking water to induce ulcerative colitis. Mice were then treated with melittin peptide alone, sulfasalazine alone, or the combination. Clinical symptoms (weight loss, stool consistency, bleeding) were monitored. Colon tissue was examined histologically for damage and inflammation. Oxidant/antioxidant balance was assessed in colon tissue.

Who was studied

C57BL/6 male mice with DSS-induced ulcerative colitis

What this study cannot tell us

Mouse model of UC (DSS-induced) does not perfectly replicate human ulcerative colitis, which involves autoimmune components. Specific melittin doses were not detailed in the abstract. No toxicity profiling of melittin itself was reported — bee venom peptides can have significant side effects at higher doses. Sample sizes per group were not specified. Short-term study without long-term follow-up.

How to read the evidence

Preclinical animal study using a standard DSS colitis model. Shows dramatic effects but is limited to mice. Melittin's known toxicity profile adds additional uncertainty about clinical translation.

When this study was published

Published in 2022 in International Immunopharmacology. Melittin research for inflammatory conditions is expanding, though clinical translation remains in early stages due to toxicity concerns.

The bigger picture

Venom-derived peptides are an increasingly studied source of therapeutic molecules. Melittin is one of the most potent, but its clinical use has been limited by toxicity concerns (it can destroy red blood cells at high doses). This study adds to a growing body of evidence that at appropriate doses, melittin's anti-inflammatory properties could be harnessed for chronic inflammatory conditions like IBD. The combination approach — pairing melittin with conventional drugs to boost efficacy and reduce side effects — is particularly promising and mirrors strategies being explored with other antimicrobial peptides.

Questions still open

What is the safe therapeutic dose range for melittin in a colitis context, and does it cause hemolysis at effective doses?
Could modified or truncated melittin analogs retain anti-inflammatory activity with reduced toxicity?
Would melittin show similar effects in chronic or recurring colitis models rather than acute DSS induction?

Common questions

Is melittin from bee venom safe to use as medicine?

Melittin is a potent peptide that can destroy cell membranes at high concentrations — it's what makes bee stings painful. At therapeutic doses in this mouse study, it was beneficial, but the safe dose range for human use has not been established. Researchers are working on modified versions that keep the anti-inflammatory benefits while reducing toxicity.

Could melittin replace current ulcerative colitis treatments?

Not yet — this is early-stage mouse research. However, the study suggests melittin could work alongside existing treatments like sulfasalazine, potentially allowing lower doses of conventional drugs (which reduces their side effects). This combination approach is more likely to reach the clinic than melittin alone.

Read the original research

Evaluation of the therapeutic effect of melittin peptide on the ulcerative colitis mouse model.

International immunopharmacology, 108, 108810

View on PubMed ↗Publisher’s paper ↗

Citation

Yaghoubi, Atieh; Amel Jamehdar, Saeid; Reza Akbari Eidgahi, Mohammad; Ghazvini, Kiarash. (2022). Evaluation of the therapeutic effect of melittin peptide on the ulcerative colitis mouse model.. International immunopharmacology, 108, 108810. https://doi.org/10.1016/j.intimp.2022.108810